Business Context and Reporting Period
This Form 8-K reports on the 2017 Annual Meeting of Stockholders held by NanoViricides, Inc. on December 8, 2017. The filing details the submission of matters to a vote of security holders, specifically the election of directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing reports the following material outcomes from the Annual Meeting:
- Attendance: Approximately 82% of the Company's outstanding voting capital stock was present in person or by proxy. This included 50,820,517 shares of common stock and 3,776,027 shares of Series A Convertible Preferred Stock.
- Director Elections (Proposal 1): Stockholders re-elected Dr. Anil Diwan, Dr. Milton Boniuk, and Dr. Mukund Kulkarni as Class I Directors for two-year terms expiring in 2019.
- Dr. Anil Diwan: 74.45% voted for.
- Dr. Milton Boniuk: 96.22% voted for.
- Dr. Mukund Kulkarni: 96.24% voted for.
- Accounting Firm Ratification (Proposal 2): Stockholders ratified the appointment of Eisner Amper, LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2018.
- 94.97% of common stock votes were cast in favor.
- Preferred Stock Voting: The 3,776,027 Series A Convertible Preferred Shares present voted in favor of both proposals. These shares vote at a rate of 9 votes per share.
Guidance, Outlook, and Risks
This filing does not provide management commentary, financial guidance, outlook, or a discussion of risks and contingencies. It strictly reports the results of the shareholder vote.
Investor Verification Checklist
- Verify the terms of the newly elected directors (Class I, two-year term expiring 2019).
- Confirm the appointment of Eisner Amper, LLP for the fiscal year ending June 30, 2018.
- Review the Company's Proxy Statement filed on October 27, 2017, for detailed descriptions of the proposals.
- Note that financial performance data is absent from this specific filing and must be sourced from periodic reports (e.g., 10-K or 10-Q).